<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT FOR ISSUERS SUBJECT TO THE
1934 REPORTING REQUIREMENTS
FORM 8-K
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 8,2001
------------------------------
KING PHARMACEUTICALS, INC.
-------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Tennessee 0--24425 54-1684963
-------------------------------------------------------------------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
501 Fifth Street, Bristol, Tennessee 37620
-------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code (423) 989-8000
-----------------------------
Not Applicable
-------------------------------------------------------------------------------
(Former name, former address and former fiscal year, if changed since
last report)
<PAGE> 2
INFORMATION TO BE INCLUDED IN THE REPORT
ITEM 5. OTHER EVENTS.
Effective January 8, 2001, King Pharmaceuticals, Inc., a Tennessee
corporation ("King") obtained an exclusive license from Novavax, Inc., a
Delaware corporation ("Novavax") to promote, market, distribute and sell
Estrasorb(TM), Novavax's topical, transdermal estrogen replacement therapy,
worldwide except in the United States, Canada, Italy, Netherlands, Greece,
Switzerland and Spain. King and Novavax will co-market Estrasorb(TM) in the
United States and Puerto Rico.
Effective as of January 8, 2001, King divested its rights to
AVC(TM) (sulfanilamide), vaginal anti-infective cream and suppositories, in the
U.S. and Puerto Rico to Novavax for $3.3 million.
Effective January 8, 2001, King entered into a Copromotion Agreement
with Novavax. Under this agreement, King and Novavax will jointly market King's
product, Nordette(R) (an oral contraceptive) in the United States and Puerto
Rico.
A press release relating to these events was issued on January 8,
2001.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(a) Financial Statements on Businesses Acquired.
Not applicable.
(b) Pro Forma Financial Information.
Not applicable.
(c) Exhibits.
The following exhibits are filed pursuant to Item 601 of
Regulation S-K:
<TABLE>
<CAPTION>
Exhibit
Number Description
------ -----------
<S> <C>
10.1 Agreement for Purchase and Sale of Assets Relating to AVC(TM)
Product Line dated as of January 8, 2001, by and between Novavax,
Inc. and King Pharmaceuticals, Inc.
10.2 Copromotion Agreement dated as of January 8, 2001, between
Novavax, Inc. and King Pharmaceuticals, Inc.
10.3 Exclusive License and Distribution Agreement dated as of January
8, 2001, between Novavax, Inc. and King Pharmaceuticals, Inc.
99.1 Press Release of King Pharmaceuticals, Inc. dated January 8, 2001
</TABLE>
- 1 -
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
KING PHARMACEUTICALS, INC.
Date: January 8, 2001
By: /s/ John M. Gregory
------------------------------------
John M. Gregory
Chairman of the Board and
Chief Executive Officer
